Results 151 to 160 of about 112,704 (293)
, 2020 RESUMEN La toxina botulínica es actualmente en tratamiento de elección para las distonía focales y algunos segmentos del cuerpo en casos de distonía generalizada.
Moreno López, Claudia Lucía +1 more
core +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Dystonia, an overview; classification, etiology and treatment
Fysioterapeuten, 2017 Introduction: Dystonia is a neurological condition which leads to involuntary muscle contractions and is little known among physiotherapists and doctors.
Jeanette Koht +3 more
doaj
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
EPHX2 Loss Promotes CRC Migration via EET‐Dependent Chemokine Elevation and Mitochondrial Defect
Cancer Science, EarlyView.Loss of EPHX2 promotes EET accumulation, which in turn enhances CXCL and ROS production, thereby promoting the migratory and invasive abilities of CRC cells. ABSTRACT Epoxide hydrolase 2 (EPHX2) is a key enzyme in fatty acid metabolism that metabolizes epoxyeicosatrienoic acids (EETs), lipid mediators involved in inflammation, angiogenesis, and ...
Jianjun Zhu +10 more
wiley +1 more source
Botulinum toxins for dystonia [PDF]
, 2017 RESUMEN La toxina botulínica es actualmente en tratamiento de elección para las distonía focales y algunos segmentos del cuerpo en casos de distonía generalizada.
Moreno López, Claudia Lucía +2 more
core
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond +6 more
wiley +1 more source
Bacterial Protein Toxins as Anticancer Agents: Clinical Potential of Pseudomonas and Anthrax Toxins
Protein toxins are biologically active polypeptides produced by a variety of organisms, including bacteria, plants, fungi, and animals. These molecules exert potent and specific toxic effects on target cells and are primarily associated with ...
Radhika Gupta +6 more
core +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and objectives Primary axillary hyperhidrosis (PAHH) results from dysregulation of the autonomic nervous system and typically begins during puberty. Treatment options for adolescents remain limited. This open‐label phase II study evaluated the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream over 8 weeks in
Rolf‐Markus Szeimies +8 more
wiley +1 more source
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland +7 more
wiley +1 more source